Triple-negative breast cancer: are we making headway at least? - Wikidata - awgldk - TriplyDB

Triple-negative breast cancer: are we making headway at least?

Triple-negative breast cancer: are we making headway at least?

http://www.wikidata.org/entity/Q36061177

about

MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer The fate of chemoresistance in triple negative breast cancer (TNBC)MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1 Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.Phytochemicals potently inhibit migration of metastatic breast cancer cells Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: novel therapeutic strategy for aggressive breast cancers.Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer.miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.MiR-153 promotes breast cancer cell apoptosis by targeting HECTD3 Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.Activators of AMPK: not just for type II diabetes.Cancer stem cells and personalized cancer nanomedicine.Double gene siRNA knockdown of mutant p53 and TNF induces apoptosis in triple-negative breast cancer cells.Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer Post-nano strategies for drug delivery: Multistage porous silicon microvectors.Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).Targeting chaperonin containing TCP1 (CCT) as a molecular therapeutic for small cell lung cancer.HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.Bioinformatics identification of dysregulated microRNAs in triple negative breast cancer based on microRNA expression profiling.miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.MiR-145 promotes TNF-α-induced apoptosis by facilitating the formation of RIP1-FADDcaspase-8 complex in triple-negative breast cancer.Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.Absence of AIF1L contributes to cell migration and a poor prognosis of breast cancer

P2860

Q26775086-0F28BB3E-B8A3-41B3-A19A-4F9566B0B94E Q26775232-61B0CE33-D165-4FED-88AC-29DC668606CF Q28554012-D100A7A4-E54F-4EF0-AB86-5513E0344264 Q33415281-57CFE430-CB19-423B-A53E-D97140415275 Q33810248-FCA6FC7B-4621-4E9D-9654-526933088E07 Q33812500-55934508-3F47-4D2A-B307-21E770F28071 Q34646291-687CF32C-EB1F-454D-8876-A2A3FF4D83EA Q36544024-054DBC4D-379D-41AB-AF5A-430B5F311914 Q36544974-64BCE20E-CF15-4BD7-9693-1CA681026402 Q37143959-E75F5945-EF70-4226-9CBD-F5DFFF88FF5E Q37278393-C305AC24-B33D-44B3-B3DF-498A72AF51F6 Q37386056-47E6AB83-02A5-4DFD-8478-6BC45EC40379 Q37520463-AEB492D2-1CB9-496F-9771-C8584DF3A376 Q37650748-8789F83B-7291-46E7-A5F6-9B19901C2E10 Q38243893-19A7418A-1ADF-41F1-B9C5-006E4EC8942D Q38702970-6571727D-894F-4C46-ABA7-F44F718C7B14 Q38726515-C8F60755-D1B7-4B19-8F07-ED99B1806DF1 Q38858554-97D6E74C-91CD-4BE8-9CC2-BA713CCB286D Q39410383-1C9B628A-EDCB-4980-94D1-B3537874EFFB Q41078110-E3396B9B-3F74-4CA3-83E7-D8600CB8E2D5 Q41489984-00D53713-1316-4F16-86E6-3FA86952D00F Q47107751-6980BC02-EEF3-4F1E-8229-C3B0A3DD947F Q47295042-441A6A36-5266-4CEA-A6FD-91E1D89DA244 Q49516769-343BAB69-8D1F-4B41-A0F7-5C795DE4E574 Q51182190-D871DCF0-86B2-4FE5-91BC-D3A0AACB1781 Q53219892-EE7936A9-4A0B-4491-B20A-00F6BDBC68AC Q54989577-4743DB08-E58C-4F2A-B2C6-3EE3BB71B865 Q58762819-2BCE6A57-B1C5-4C0A-88E0-362F3D6BA1FB

P2860

Triple-negative breast cancer: are we making headway at least?

http://www.wikidata.org/entity/Q36061177

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Triple-negative breast cancer: are we making headway at least?

@ast

Triple-negative breast cancer: are we making headway at least?

@en

type

label

Triple-negative breast cancer: are we making headway at least?

@ast

Triple-negative breast cancer: are we making headway at least?

@en

prefLabel

Triple-negative breast cancer: are we making headway at least?

@ast

Triple-negative breast cancer: are we making headway at least?

@en

P1433

Q36061177-264C086B-E735-442B-9BD6-736BAD33A751

P1476

Q36061177-3993652C-5A5C-4B65-B8E8-5A5E459AD43B

P2093

Q36061177-1DB0DEF3-C435-4765-B79E-0FB427B55AFC

Q36061177-600378E0-0C9C-448F-BC6A-1E2F898D8886

Q36061177-62B9983E-3474-4157-A94A-4A7D4DAB6E5B

Q36061177-97310D37-FAD4-402D-A262-0E0211EC6264

P2860

Q36061177-032FCD06-88EF-40CF-8258-5045CDFE1AB0

Q36061177-0340304B-8639-468F-9EDE-454546A8EB64

Q36061177-08CE5633-B1C7-4E43-B858-8C0E32A3B043

Q36061177-0C14106B-26D8-4424-805D-840CBE83DDDE

Q36061177-0C560DC9-7367-4AFA-9371-21C4A32BE28E

Q36061177-106C8D4B-24C8-41A7-B181-64796D2FA30E

Q36061177-19782B7D-816D-40EE-9C4A-EEF47E6D72C8

Q36061177-248B5449-7F1F-4AF1-A1C8-33A829E280FB

Q36061177-29611357-84AC-4E13-B7AE-13F22A734887

Q36061177-2B59B9F4-D74F-4BB0-A82C-6E85313AD756

P304

Q36061177-EC6433A3-2BE2-4E6B-96A8-7BB546C6BA6B

P31

Q36061177-D407A254-31DA-4F3C-8F67-2199186A4C14

P356

Q36061177-7D2A046B-08B9-4CA5-A2EB-5AE42E7B9B1E

P433

Q36061177-75D8B72C-311C-4DD8-99F3-BCCA42A1ECE0

P478

Q36061177-13F05A00-B71A-4A4C-B68D-48A67DEEA37A

P50

Q36061177-C685CFA1-CFE6-42D8-A242-46D7B247DDC7

P577

Q36061177-D780D424-0528-4BF3-8FAE-C9768AEA283E

P5875

Q36061177-35D9A3D3-A7D1-471F-83CB-9EDB6D8EC1FB

P698

Q36061177-BE6DBADA-FACC-4B76-AB2A-8B9B86A9694E

P932

Q36061177-881662AE-1EA2-4E31-84D7-11B6F06C77E1

P356

1758834012444711

P1433

Therapeutic advances in medical oncology

P1476

Triple-negative breast cancer: are we making headway at least?

@en

P2093

Celine Bihan

http://www.w3.org/2001/XMLSchema#string

Fabrice Andre

http://www.w3.org/2001/XMLSchema#string

Monica Arnedos

http://www.w3.org/2001/XMLSchema#string

Suzette Delaloge

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Molecular portraits of human breast tumours

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Hallmarks of 'BRCAness' in sporadic cancers

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

P304

195-210

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834012444711

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Suzette Delaloge

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228106365

http://www.w3.org/2001/XMLSchema#string

P698

22754593

http://www.w3.org/2001/XMLSchema#string

P932

3384094

http://www.w3.org/2001/XMLSchema#string